In an elderly patient with urinary symptoms who is taking several antihypertensive medications, what is the most appropriate action when they request an alpha-blocker?

In an elderly patient with urinary symptoms who is taking several antihypertensive medications, what is the most appropriate action when they request an alpha-blocker?

• A. Proceed with sale and monitor blood pressure
• B. Refuse supply due to potential interaction with his current antihypertensive medications and advise a GP review
• C. Recommend trying a different urinary symptom relief
• D. Refer to a pharmacist for further advice

Answer: (B)

The main idea here is safety in polypharmacy. Alpha-blockers used for urinary symptoms can lower blood pressure and cause orthostatic hypotension. When a patient is elderly and already taking several antihypertensive medicines, adding an alpha-blocker increases the risk of excessive blood pressure fall, dizziness, fainting, and falls. Because of this interaction risk and the need to reassess the overall treatment plan, the most appropriate action is to refuse supply and advise a GP review. This allows a clinician to reassess urinary symptoms, evaluate all current medications for interactions, and decide on a safe, effective treatment strategy. If helpful, you can discuss non-pharmacological approaches or safer alternatives under medical guidance, but the decision should come from a clinician after reviewing the full medication profile.

The main idea here is safety in polypharmacy. Alpha-blockers used for urinary symptoms can lower blood pressure and cause orthostatic hypotension. When a patient is elderly and already taking several antihypertensive medicines, adding an alpha-blocker increases the risk of excessive blood pressure fall, dizziness, fainting, and falls. Because of this interaction risk and the need to reassess the overall treatment plan, the most appropriate action is to refuse supply and advise a GP review. This allows a clinician to reassess urinary symptoms, evaluate all current medications for interactions, and decide on a safe, effective treatment strategy. If helpful, you can discuss non-pharmacological approaches or safer alternatives under medical guidance, but the decision should come from a clinician after reviewing the full medication profile.